Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy
Chau‐Ting Yeh, Rong‐Nan Chien, Chia‐Ming Chu, Yun‐Fan Liaw – 30 December 2003 – Tyrosine‐methionine‐aspartate‐aspartate (YMDD)‐motif mutants may emerge and elicit immune clearance during prolonged lamivudine treatment. The aim of this study was to investigate the virological events following development of the original mutants. Twenty‐three patients who developed YMDD‐motif mutants during the Asian lamivudine trial were included. Serial serum samples from these patients were subjected to sequence analysis to identify new mutants.